What Makes Us Unique

Complete Phase is a specialist early-phase CRO

Designed specifically for Phase I–II studies. We combine senior-led delivery, lean execution, and cost efficiency to give you speed, clarity, and control when it matters most.

Senior-Led

Direct access to experienced operators from protocol review through study close-out.

Agile

Rapid decisions, flexible teams, and streamlined processes that keep studies moving.

Transparent

Clear communication, predictable budgets, and no surprises.

Industry Best Practices

Our team are clinical operation experts, guiding your research from feasibility to closeout.

Plan

Our expert team provides strategic direction and tailored advice for every step of your clinical trial planning.

Execute

Our dedicated Project Manager ensures timely execution of your study, tracking progress and consistently providing feedback to the sponsor.

Review

We'll routinely review, share, and discuss your study's progress and milestones to ensure quality, timeliness, and budget adherence.

The Australian Advantage

We will assist you in leveraging Australia's clinical ecosystem to execute your clinical trial program to its fullest potential. Australian data is globally accepted, and early-phase studies conducted in Australia meet ICH-GCP standards and are fully recognized by the FDA, EMA, MHRA, and other major regulators.

Australia has an efficient and streamlined regulatory process with clinical trial approvals in as little as 4 weeks. Proposals are submitted directly to an Ethics Committee, bypassing the need for a lengthy IND application.

Australia is internationally renowned for producing top-tier scientific and medical research. Study sites and CROs here uphold both local and global standards, ensuring the delivery of exceptional research services.

The Australian Government's Research and Development (R&D) Tax Incentive provides eligible companies with up to 43.5% cash back on clinical trial expenses, encouraging investment in eligible business activities.

Efficient Regulatory Processes  
Internationally Recognised Standards
Lowered drug development expenses